Rigor Reviewed

Rigor-Reviewed Manuscript

Restrictive vs Liberal Transfusion Strategy in Patients With Acute Brain Injury: The TRAIN Randomized Clinical Trial.

Name: Αlpha¹ Rigor Record — Restrictive vs Liberal Transfusion Strategy in Patients With Acute Brain Injury: The TRAIN Randomized Clinical Trial.
Item: Restrictive vs Liberal Transfusion Strategy in Patients With Acute Brain Injury: The TRAIN Randomized Clinical Trial.
Rating: 96
Author: Αlpha¹

Taccone FS, Rynkowski CB, Møller K, Lormans P, Quintana-Díaz M, Caricato A, Cardoso Ferreira MA, Badenes R, Kurtz P, Søndergaard CB, Colpaert K, Petterson L, Quintard H, Cinotti R, Gouvêa Bogossian E, Righy C, Silva S, Roman-Pognuz E, Vandewaeter C, Lemke D, Huet O, Mahmoodpoor A, Blandino Ortiz A, van der Jagt M, Chabanne R, Videtta W, Bouzat P, Vincent JL, TRAIN Study Group

Paper source

Read full text (PMC)PDF

Embed this Rigor badge

Αlpha¹ Rigor Review — 3.25★ (Adequate), 0 critical, 2 high issues for “Restrictive vs Liberal Transfusion Strategy in Patients With Acute Brain Injury: The TRAIN Randomized Clinical Trial.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 16, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

3.25 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×3−1.5★
ReportingData & code availability partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

No data or code availability links were detected to verify.

Problems surfaced3 types

Numerical inconsistencies1

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Data authenticity concerns1

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Other integrity concernAssessed

Reporting gaps1

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data/code availability incompleteAssessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

The paper is a well-designed, multicenter, phase 3 randomized clinical trial with rigorous methodology, clear reporting, and appropriate statistical analysis. The main weakness is the lack of a detailed data sharing statement in the main text, which is only referenced to a supplement.

This is an interventional study (randomized clinical trial). The evaluation covered all eight dimensions; several sub-criteria were not applicable (e.g., species/strain, housing, antibodies, cell lines) due to the human clinical trial nature. The reviewers agreed on all dimensions, so no divergence was present.

4 major claims checked against the paper's own evidence: all adequately supported.

Efficacy claim is anchored to an adequate endpoint and a meaningful effect.

Recomputed 4 tests: 4 consistent, 0 inconsistent; 4 via agent-written checks.

3 integrity concerns flagged (0 high).

Reporting

Eight Dimensions7 pass · 1 warn

The introduction cites several randomized trials and observational studies on transfusion thresholds in critically ill patients and specifically in acute brain injury, acknowledging the uncertainty and limitations of prior work. The rationale linking the premise to the study objectives is explicit, and the study addresses gaps in prior research by targeting a specific population and using a pragmatic design.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The paper establishes a clear scientific premise by citing prior randomized trials and observational studies, and provides a logical rationale for the study.

Evidence

paraphrase[Introduction, paragraphs 1-3]

“Several randomized clinical trials have been conducted to compare different transfusion strategies in this patient population, and most have suggested that a restrictive transfusion strategy may be as safe and effective as a more liberal approach. None of these studies specifically targeted patients with acute brain injury.”

paraphrase[Introduction, paragraph 3]

“Given the absence of clear evidence on hemoglobin transfusion thresholds and the existing safety concerns associated with transfusion, we initiated the Transfusion Strategies in Acute Brain Injured Patients (TRAIN) trial to assess the impact on neurological outcome of using different hemoglobin thresholds to guide red blood cell transfusions in patients with acute brain injury necessitating admission to the intensive care unit (ICU).”

direct quote[Discussion, paragraph 2]

“The main differences between that trial and ours include the hemoglobin transfusion threshold selected for the control group (10 vs 9 g/dL), the definition of unfavorable neurological outcome (GOS-E score of 1-4 vs 1-5), the predefined subgroup analyses, and the target population (TBI vs a more heterogeneous acute brain injury cohort).”

PASSReviewer 2· 95% conf

The paper establishes a clear scientific premise by citing prior randomized trials and observational studies, and provides a logical rationale for the study.

Evidence

paraphrase[Introduction, paragraphs 1-3]

paraphrase[Introduction, paragraph 3]

paraphrase[Introduction, paragraph 2]

“These findings, being observational, did not establish the optimal hemoglobin threshold for transfusion.”

Randomization used a web-based computer-generated sequence with variable block sizes and stratification. Outcome assessors were blinded, and the open-label design is acknowledged. A priori sample size calculation was performed and adjusted with ethics approval. Inclusion/exclusion criteria were detailed, and the analysis population (modified intention-to-treat) is defined. The trial is registered and follows CONSORT.

Sub-criteria

controlsN/A

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The trial design is rigorous with adequate randomization, blinding of outcome assessors, sample size calculation, and pre-specified inclusion/exclusion criteria.

Evidence

paraphrase[Methods, Randomization and Blinding]

“Randomization was conducted using a web-based, computer-generated random sequence with variable block sizes of 4, 6, and 8. Stratification was performed based on center, type of brain injury (TBI, subarachnoid hemorrhage, or intracerebral hemorrhage), and Glasgow Coma Scale score at the time of randomization (3-5, 6-9, or 10-13).”

paraphrase[Methods, Randomization and Blinding]

“The final neurological evaluations of patients were conducted by assessors who were blinded to the treatment assignments.”

paraphrase[Methods, Sample Size Calculation]

“The initial sample size calculation was based on estimated mortality and poor neurological outcome rates of 15% and 35%, respectively (corresponding to a GOS-E score of 1-5 in 50% of cases). This calculation indicated that each group was required to have 2095 patients to achieve a statistical power of 90% at a 2-sided α = .05 or less.”

PASSReviewer 2· 95% conf

The trial design is rigorous with adequate randomization, blinding of outcome assessors, sample size calculation, and pre-specified inclusion/exclusion criteria.

Evidence

paraphrase[Methods, Randomization and Blinding]

“Randomization was conducted using a web-based, computer-generated random sequence with variable block sizes of 4, 6, and 8.”

paraphrase[Methods, Randomization and Blinding]

“The final neurological evaluations of patients were conducted by assessors who were blinded to the treatment assignments.”

paraphrase[Methods, Sample Size Calculation]

“The initial sample size calculation was based on estimated mortality and poor neurological outcome rates of 15% and 35%, respectively (corresponding to a GOS-E score of 1-5 in 50% of cases).”

The paper reports age, sex, and a range of clinical characteristics in Table 1. Since this is a human trial, species/strain and housing conditions are not applicable. Sex is reported for both groups, and both sexes are enrolled, so no single-sex justification is needed.

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Demographic and clinical characteristics are well reported, including age, sex, and relevant comorbidities.

Evidence

direct quote[Table 1]

“Age, mean (SD), y 52 (16) 51 (16) Sex, No. (%) Female 179 (45.1) 197 (46.6) Male 218 (54.9) 226 (53.4)”

direct quote[Table 1]

“Medical history, No. (%) Diabetes 25 (6.3) 24 (5.7) Chronic obstructive pulmonary disease 21 (5.3) 22 (5.2)”

PASSReviewer 2· 90% conf

Demographic and clinical characteristics are well reported, including age, sex, and key health status variables.

Evidence

direct quote[Table 1]

“Sex, No. (%) Female 179 (45.1) 197 (46.6) Male 218 (54.9) 226 (53.4)”

direct quote[Table 1]

“Age, mean (SD), y 52 (16) 51 (16)”

The paper states that approvals were obtained from ethics committees in each hospital and that written informed consent was obtained from legal surrogates. It also mentions adherence to CONSORT and the Declaration of Helsinki implicitly. The trial is registered, and the protocol was published.

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Ethics approval and informed consent are adequately described.

Evidence

direct quote[Methods, Trial Design]

“After obtainment of approvals from ethics committees in each hospital, patients were screened for eligibility.”

paraphrase[Methods, Trial Design]

“Written informed consent was obtained from legal surrogates before enrollment.”

direct quote[Methods, Trial Design]

“This study adhered to the Consolidated Standards of Reporting Trials (CONSORT) reporting guidelines.”

PASSReviewer 2· 90% conf

Ethics approval and informed consent are adequately described.

Evidence

direct quote[Methods, Trial Design]

“After obtainment of approvals from ethics committees in each hospital, patients were screened for eligibility.”

paraphrase[Methods, Trial Design]

“Written informed consent was obtained from legal surrogates before enrollment.”

The trial uses red blood cell transfusions as the intervention, which is described in terms of thresholds and administration. The paper does not use antibodies, cell lines, or other bench reagents, so those are not applicable. Statistical software (SPSS version 29.0) is identified.

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 85% conf

The investigational product (red blood cell transfusion) is adequately described, and statistical software is identified.

Evidence

paraphrase[Methods, Trial Intervention]

“Following randomization, all patients received 1 unit of packed red blood cells at a time when they met their allocated hemoglobin concentration threshold.”

direct quote[Methods, Statistical Analysis]

“Statistical analyses were conducted using SPSS version 29.0 (IBM).”

PASSReviewer 2· 85% conf

The investigational product (red blood cell transfusion) is adequately described, and statistical software is identified.

Evidence

direct quote[Methods, Statistical Analysis]

“Statistical analyses were conducted using SPSS version 29.0 (IBM).”

paraphrase[Methods, Trial Intervention]

“Following randomization, all patients received 1 unit of packed red blood cells at a time when they met their allocated hemoglobin concentration threshold.”

The paper names statistical tests (Wilcoxon rank sum, Fisher exact, chi-square, log-binomial regression, Cox proportional hazards, ordinal logistic regression) and reports effect sizes with 95% CIs. Exact p-values are provided for the primary outcome. Software is identified. Data presentation includes per-group n and confidence intervals. Mathematical plausibility checks were not possible for all values, but no obvious errors were found.

Sub-criteria

tests namedADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Statistical methods are well described, with named tests, effect sizes with confidence intervals, and appropriate handling of missing data.

Evidence

direct quote[Methods, Statistical Analysis]

“Continuous variables are summarized using medians and IQRs and were analyzed using the Wilcoxon rank sum test. Categorical variables were analyzed using the Fisher exact test.”

direct quote[Results, Study Outcomes]

“absolute difference, −10.0% [95% CI, −16.5% to −3.6%]; adjusted relative risk, 0.86 [95% CI, 0.79-0.94]; P = .002”

direct quote[Methods, Statistical Analysis]

“Statistical analyses were conducted using SPSS version 29.0 (IBM).”

PASSReviewer 2· 90% conf

Statistical methods are well described, with named tests, effect sizes with confidence intervals, and appropriate handling of missing data.

Evidence

direct quote[Methods, Statistical Analysis]

“Continuous variables are summarized using medians and IQRs and were analyzed using the Wilcoxon rank sum test. Categorical variables were analyzed using the Fisher exact test.”

direct quote[Results, Study Outcomes]

“absolute difference, −10.0% [95% CI, −16.5% to −3.6%]; adjusted relative risk, 0.86 [95% CI, 0.79-0.94]; P = .002”

The paper mentions 'Data Sharing Statement: See Supplement 4.' but does not provide details in the main text. Since this is a clinical trial with patient data, managed access is acceptable, but the statement is vague without specifying the mechanism or conditions. No code sharing is applicable.

Sub-criteria

code sharingN/A

accession numbersN/A

repository depositN/A

data availability statementINADEQUATE

Per reviewer (2) — the votes behind the verdict

WARNReviewer 1· 80% conf

A data sharing statement is mentioned but not detailed in the main text; no repository or accession numbers are provided.

Evidence

direct quote[Article Information, Data Sharing Statement]

“Data Sharing Statement: See Supplement 4.”

WARNReviewer 2· 80% conf

A data sharing statement is mentioned but not detailed in the provided text; no repository or accession numbers are given.

Evidence

direct quote[Article Information]

“Data Sharing Statement: See Supplement 4.”

The trial is registered (NCT02968654). The paper states adherence to CONSORT guidelines. All prespecified outcomes are reported, including secondary outcomes and adverse events. Limitations are thoroughly discussed. Conclusions are proportional to the evidence. Funding and conflicts of interest are disclosed.

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineADEQUATE

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper is transparent with trial registration, CONSORT adherence, discussion of limitations, and proportional conclusions.

Evidence

direct quote[Abstract, Trial Registration]

“TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT02968654”

direct quote[Discussion, Limitations]

“First, the awareness of study group assignments by investigators and clinicians, coupled with an incomplete assessment of all concomitant interventions, could potentially introduce bias.”

direct quote[Article Information, Funding/Support and Conflict of Interest Disclosures]

“Funding/Support: This study was funded by the ESICM NeXT grant and La Fondation des Geules Cassées.”

PASSReviewer 2· 95% conf

The paper is transparent, with trial registration, CONSORT adherence, discussion of limitations, and proportional conclusions.

Evidence

direct quote[Abstract]

“TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT02968654”

direct quote[Methods, Trial Design]

“This study adhered to the Consolidated Standards of Reporting Trials (CONSORT) reporting guidelines.”

direct quote[Discussion, Limitations]

“First, the awareness of study group assignments by investigators and clinicians, coupled with an incomplete assessment of all concomitant interventions, could potentially introduce bias.”

1 copyedit issue flagged: mostly typo.

Checked 30 references by DOI: 29 verified — 1 no DOI (shown, not verified).

Reproducibility

Registered (2 IDs: ClinicalTrials.gov). Reporting guideline cited: CONSORT.

Αlpha¹ Rigor Action ItemsFinal pass before journal submission

The published work is robust and well-reported, with only a minor data-sharing transparency gap. An informed reader should weigh the retrospective registration timing (first submitted to ClinicalTrials.gov after the study start date) and the limited statistical verification coverage, but these do not undermine the core findings. No erratum or correction is warranted based on the current evidence.

1.
HIGHdata code
In the Article Information section, replace the 'Data Sharing Statement: See Supplement 4.' with a full statement specifying the data access mechanism (e.g., contact the corresponding author or a data access committee), conditions, and timeframe.
The current statement is vague and does not meet transparency expectations for a data-driven clinical trial.
2.
HIGHdata code
If individual patient data cannot be shared openly, state that data are available on reasonable request with a clear process, or deposit de-identified aggregate data in a public repository with a DOI.
This would enhance reproducibility and align with journal data-sharing requirements.
3.
MEDIUMreporting
Add a link to the full study protocol and statistical analysis plan in the main text or supplement.
This improves transparency and allows readers to verify pre-specified outcomes and analyses.
4.
MEDIUMdata code
If any bespoke code was used for statistical analysis, provide it in a public repository with version control.
Sharing analysis code enhances reproducibility.
5.
MEDIUMreporting
Ensure the supplement containing the data sharing statement is accessible and clearly referenced in the main text.
The current reference is vague and may not be easily located by readers.
6.
LOWcopyedit
In the Abstract Results, consider rephrasing the sentence for clarity: 'Eight hundred fifty patients were randomly assigned to a liberal (n=408) or restrictive (n=442) transfusion strategy.'
The current sentence is grammatically correct but could be more concise.
7.
LOWreporting
Consider adding a note about the availability of the electronic case report form or data dictionary.
This would further support data transparency and reproducibility.

Full text (62,266 chars)Analyzed: Aug 16, 2026

Start the discussion on JRNLClub

Community discussion on jrnlclub.com

Read alongside

Restrictive vs Liberal Transfusion Strategy in Patients With Acute Brain Injury: The TRAIN Randomized Clinical Trial.

Read full text (PMC)

Open PDF

DOI

10.1001/jama.2024.20424

Share this Rigor Review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/bb64fe58-d67e-4e71-9b37-4be72b8cc574" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/bb64fe58-d67e-4e71-9b37-4be72b8cc574/badge" alt="Αlpha¹ Rigor Review — 3.25★ (Adequate), 0 critical, 2 high issues for “Restrictive vs Liberal Transfusion Strategy in Patients With Acute Brain Injury: The TRAIN Randomized Clinical Trial.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Rigor Record.

Record fingerprint

2ffc3ba354d6b325d5c6f9c2710193daae700448e387928e299c8c8c37f066d2

Verify via API

Issued Aug 16, 2026Engine 7.39.0

Αlpha¹ assesses methodological rigor, not the importance of the findings. See how we calibrate →